What were the main drivers of AmerisourceBergen's revenue growth in fiscal year 2007?

The primary driver of revenue growth was the Pharmaceutical Distribution segment, which saw a 9% increase. This was largely fueled by strong performance in AmerisourceBergen Drug Corporation (ABDC) and particularly the AmerisourceBergen Specialty Group (ABSG), which experienced a 23% revenue increase due to its outperformance in the specialty pharmaceutical market, especially in oncology.

What significant acquisitions did AmerisourceBergen complete during fiscal year 2007?

In fiscal year 2007, AmerisourceBergen completed several acquisitions, including Health Advocates, Inc. (a provider of Medicare set-aside services), I.G.G. of America, Inc. (a specialty pharmacy), Access M.D., Inc. (a Canadian specialty pharma services company), and Xcenda LLC (a consulting business). Most notably, in October 2007, shortly after the fiscal year-end, the company acquired Bellco Health, a New York-based pharmaceutical distributor, for approximately $181 million.

What impact did government regulations and healthcare policy changes have on AmerisourceBergen's business?

The company noted that legislative and regulatory changes, such as the Deficit Reduction Act of 2005 impacting Medicaid reimbursement rates for generics, could potentially affect profitability. Additionally, changes in Medicare coverage policies for anemia drugs had a negative impact on ABSG's sales. The company also highlighted ongoing scrutiny and potential changes in healthcare delivery and reimbursement, which could impact its business.

How did AmerisourceBergen manage its capital resources and shareholder returns?

AmerisourceBergen actively managed its capital by repurchasing a significant amount of its common stock, spending $1.4 billion in fiscal year 2007. The company also demonstrated a commitment to returning capital to shareholders by increasing its quarterly cash dividend by 50% in November 2007. Its robust operating cash flow and available credit facilities provided sufficient resources for operations, capital expenditures, and share repurchases.

COR 10-K FY2007 Annual Report — Revenue, Net Income, EPS

Summary

AmerisourceBergen Corporation (COR) reported strong revenue growth in fiscal year 2007, driven by its Pharmaceutical Distribution segment, which accounts for the vast majority of its business. The company saw a 9% increase in operating revenue to $61.7 billion, largely due to performance in its AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG) divisions. ABSG, in particular, demonstrated robust growth, exceeding overall market expansion, primarily in its oncology-focused distribution and services. The company continued its strategic focus on optimizing its distribution and service businesses through both organic growth initiatives and targeted acquisitions, including the notable acquisition of Bellco Health for $181 million. While the company faced some headwinds, such as increased bad debt expense and the impact of declining anemia drug sales on ABSG, its overall financial performance remained solid. The company also actively managed its capital structure, repurchasing a significant amount of its stock and increasing its quarterly dividend.

Financial Highlights

30 data points

Beta

Revenue

$65.67B

0.0% Gross Margin

Net Income

$469.17M

0.0% Net Margin

EPS (Diluted)

$1.25

Cash & Equivalents

$640.20M

Free Cash Flow

$1.10B

Financial Statements

Beta

Revenue	$65.67B
Cost of Revenue	$63.45B
Gross Profit	$2.22B
SG&A Expenses	$1.34B
Operating Income	$788.74M
Net Income	$469.17M
EPS (Basic)	$1.27
EPS (Diluted)	$1.25
Shares Outstanding (Basic)	370.36M
Shares Outstanding (Diluted)	375.77M

Key Highlights

1Operating revenue increased by 9% to $61.7 billion in fiscal year 2007, primarily driven by the Pharmaceutical Distribution segment.
2The AmerisourceBergen Specialty Group (ABSG) showed strong performance with a 23% increase in operating revenue, outperforming the broader market.
3The company completed several acquisitions, including Bellco Health for $181 million, to strengthen its market position and service offerings.
4AmerisourceBergen continued its facility consolidation efforts, completing the Optimiz® program which reduced its US distribution facilities from 51 to 26, leading to cost savings.
5The company repurchased $1.4 billion of its common stock during fiscal year 2007 and announced a new $850 million repurchase program.
6Despite a charge related to tetanus-diphtheria vaccine inventory and a loss from a legal matter concerning Bridge Medical, net income remained stable at $469.2 million.
7The company adjusted its dividend policy, increasing the quarterly cash dividend by 50% to $0.075 per share.

Cencora, Inc. Annual Report, Year Ended Sep 30, 2007

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions